

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44		A1	(11) International Publication Number: WO 98/22108
			(43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/20955		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 17 November 1997 (17.11.97)			
(30) Priority Data: 60/031,468 20 November 1996 (20.11.96) US 9700559.9 13 January 1997 (13.01.97) GB			
(71) Applicant (<i>for all designated States except US</i>): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		Published <i>With international search report.</i>	
(72) Inventor; and			
(75) Inventor/Applicant (<i>for US only</i>): CHANG, Linda, L. [CA/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(54) Title: TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE			
(57) Abstract			
2-4-Diaryl-5-pyridylimidazoles are glucagon antagonists. The compounds block the action of glucagon at its receptor. Thus, the compounds can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon. Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE

BACKGROUND OF THE INVENTION

5 The present invention relates to triaryl substituted imidazoles which antagonize the metabolic effect of glucagon.

Diabetes is a disease process derived from multiple causative factors and characterized by elevated levels of plasma glucose.

10 Uncontrolled hyperglycemia is associated with an increased risk for microvascular and macrovascular diseases, including nephropathy, retinopathy, hypertension, stroke and heart disease. Control of glucose homeostasis is, therefore, a major approach to the treatment of diabetes.

15 Glucagon is a major counter regulatory hormone that attenuates the inhibition of liver gluconeogenesis by insulin. Glucagon receptors are found primarily in the liver, although their presence has been documented in kidney, pancreas, adipose tissues, heart, smooth muscles of vascular tissues, and some regions of the brain, stomach and adrenal glands.

20 Type II diabetics have elevated levels of plasma glucagon and increased rates of hepatic glucose production. The rate of hepatic glucose production positively correlates with fasting blood glucose levels in type II diabetics. Therefore, antagonists of glucagon are useful in improving insulin responsiveness in the liver, decreasing the rate of gluconeogenesis and lowering the rate of hepatic glucose output resulting in a decrease in the levels of plasma glucose.

25 A monoclonal antibody to glucagon (Glu-mAb) has been utilized to test the acute effects of attenuation of glucagon action in streptozotocin-treated diabetic rats (Brand et al., Diabetologia 37:985, 1994). In contrast to a control antibody, injection of Glu-mAb attenuated the postprandial increase in blood glucose in moderately hyperglycemic rats (ie., rats with a moderate impairment in insulin secretion). In severely hyperglycemic rats (ie., rats with severely impaired insulin secretion), Glu-mAb injection did not lower blood glucose levels, but potentiated the hypoglycemic effect of a suboptimal dose of insulin.

- 2 -

These data suggest that attenuation of the action of glucagon in these models leads to increased sensitivity to the action of insulin, but does not lead to decreased blood glucose levels in the absence of insulin. On the other hand, a monoclonal antibody to glucagon was effective in lowering 5 plasma glucose levels in diabetic rabbits independent of insulin effects(Brand et al., *Diabetes*, 45:1076 (1996). While these data support the notion that antagonism of glucagon action will provide beneficial therapy for both type I and type II diabetics, this hypothesis could be more rigorously tested if a specific non-peptidyl glucagon antagonist 10 were available.

The regulation of glucagon homeostasis is also mediated by the hormone insulin, produced in the β cells of the pancreas. Deterioration of these cells is typically observed in Type I diabetics, and abnormalities in the function of these cells may occur in patients 15 presenting the symptoms of Type II diabetes. Thus, a glucagon antagonist might have utility in treating Type I diabetics.

The glucagon receptor is expressed in kidney tissues where glucagon has been demonstrated to have an effect on electrolyte homeostasis including the ions sodium, potassium, chloride, magnesium, 20 calcium, and phosphate and the non-electrolytes urea and water (Ahloulay et al., *Am. J. Physiol.*, 269: F225, 1995). A glucagon antagonist may have use in treating disorders involving electrolyte imbalance. The kidney is also gluconeogenic in response to glucagon (Amores et al., *Molec. Cell. Biochem.*, 137: 117, 1994) and an antagonist 25 would act to lower glucose production in kidney furthering the treatment of diabetes.

Glucagon receptors are present in the heart and in smooth muscles. Glucagon has a direct effect on cardiac output and heart rate (Glick et al., *Circ. Res.*, 22: 789 (1968); Farah, *Pharm. Rev.*, 35: 181, 30 1983). A strong correlation has been observed in patients with hypertension and elevated plasma glucagon levels resulting from impaired hepatic catabolism (Silva et al., *Heptatology*, 11: 668, 1990). Antagonism of the effects of elevated glucagon levels may have an effect on certain types of hypertension, thus a glucagon antagonist may

- 3 -

have utility in the treatment of certain types of hypertension associated with elevated glucagon production.

- The primary role for glucagon and glucagon receptors associated with adipose tissues is to induce lipolysis, thus providing free
5 fatty acids as a substrate for fat burning tissues (Saggesson et al., *Biochem. J.*, 238: 387, 1986). An antagonist to this effect might be useful in treating conditions where there is excessive lipolysis of fat stores resulting from elevated glucagon levels, such as wasting disease (cachexia).
- 10 Glucagon and glucagon receptors have been localized to the hippocampus region of the brain (Hoosein and Gurd, *Proc. Natl. Acad. Sci. USA*, 81: 4368, 1984). This discovery suggests that glucagon may have a neuroendocrine role in initiating or elaborating basic behavior or somatic motor programs. Since glucagon secretion is increased in
15 response to low blood glucose levels, increased glucagon levels in the brain may initiate behavior to respond to low glucose levels, such as eating. Thus, chronic hyperglucagonemia may also result in a constant craving for food resulting in obesity. A glucagon antagonist may have utility in treating obesity by altering feeding behavior associated with a
20 response to glucagon.

The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant compounds thus are useful as antidiabetic agents. Glucagon may have other direct effects on cardiac output, lipolysis, and feeding behavior and therefore may be useful as antihypertensive, anti-cachexia or antiobesity agents.
25

SUMMARY OF THE INVENTION

30 The present invention relates to 2,4-diaryl-5-pyridyl imidazoles which are glucagon receptor antagonists. These compounds are therefore useful for the treatment of diseases caused by excessive levels of glucagon, including diabetes and certain types of hypertension, cachexia and obesity.


- 4 -

Also included in the invention are pharmaceutical compositions which comprise a compound of formula I in combination with a pharmaceutically acceptable carrier.

- Also included in the invention are methods of treating
5 glucagon-mediated diseases, comprising administering to a mammalian patient in need of such treatment an amount of a compound of formula I which is effective to treat said diseases.

DETAILED DESCRIPTION OF THE INVENTION

- 10 The present invention provides a method of treating glucagon-mediated diseases, in a mammal in need of such treatment, which comprises administering to said mammal an effective amount of a glucagon antagonist of formula (I):



15

wherein

- R₁ is 4-pyridyl, 4-pyrimidinyl or 4-quinolyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
20 (1) halogen,
(2) -CN,
(3) C₁-10 alkyl-, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
(4) -O-C₁-10alkyl,
(5) -S-C₁-10alkyl,
(6) -NR₈R₉, and
(7) -NO₂;

- 5 -

R₂ is phenyl, 1-naphthyl, 2-naphthyl or heteroaryl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of

R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of

- 15 (1) C₁-3alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 (2) -O-C₁-2alkyl,
 (3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,

20 (4) -O-heteroaryl,
 (5) -NO₂,
 (6) halogen,
 (7) -S-CH₃,
 (8) -S(O)_mC₁₋₂alkyl,
 (9) -S(O)_mOR₈,
 (10) -S(O)_mNR₈R₉,

- 25 (11) -O(CR₁₀R₂₀)_pNR₈R₉,
 (12) -C(O)C₁₋₂alkyl,
 (13) -CO₂C₁₋₂alkyl,
 (14) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
 (15) -ZC(O)R₈,

30 (16) -CN,
 (17) -C(Z)NR₈R₉,
 (18) amino,
 (19) NR₁₀C(Z)R₈,
 (20) -C(Z)NR₈OR₉,

- 6 -

- (21) NR₁₀C(Z)NR₈R₉,
- (22) -NR₁₀S(O)_mR₁₁,
- (23) -C(=NOR₂₁)R₈,
- (24) -NR₁₀C(=NR₁₅)SR₁₁,
- 5 (25) -NR₁₀C(=NR₁₅)NR₈R₉,
- (26) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
- (27) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,
- (28) -NR₁₀C(O)C(O)NR₈R₉,
- (29) -NR₁₀C(O)C(O)OR₁₀,
- 10 (30) -NR₁₀S(O)_mNR₇R₁₇,
- (31) -C(=NR₁₃)NR₈R₉,
- (32) -C(=NOR₁₃)NR₈R₉,
- (33) -C(=NR₁₃)ZR₁₁,
- (34) -OC(Z)NR₈R₉,
- 15 (35) -NR₁₀S(O)_mCF₃,
- (36) -NR₁₀C(Z)OR₁₀,
- (37) 5-(R₁₈)-1,2,4-oxadiazol-3-yl or
- (38) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl;

R₄ is

- 20 (1) -OR₈,
- (2) -NO₂,
- (3) halogén
- (4) -S(O)_mR₁₁,
- (5) -SR₈,
- 25 (6) -S(O)_mOR₈,
- (7) -S(O)_mNR₈R₉,
- (8) -NR₈R₉,
- (9) -O(CR₁₀R₂₀)_pNR₈R₉,
- (10) -C(O)R₈,
- 30 (11) -CO₂R₈,
- (12) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
- (13) -ZC(O)R₈,
- (14) -CN,
- (15) -C(Z)NR₈R₉,

- 7 -

- (16) NR₁₀C(Z)R₈,
- (17) -C(Z)NR₈OR₉,
- (18) NR₁₀C(Z)NR₈R₉,
- (19) -NR₁₀S(O)_mR₁₁,
- 5 (20) -C(=NOR₂₁)R₈,
- (21) -NR₁₀C(=NR₁₅)SR₁₁,
- (22) -NR₁₀C(=NR₁₅)NR₈R₉,
- (23) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
- (24) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,
- 10 (25) -NR₁₀C(O)C(O)NR₈R₉,
- (26) -NR₁₀C(O)C(O)OR₁₀,
- (27) -C(=NR₁₃)NR₈R₉,
- (28) -C(=NOR₁₃)NR₈R₉,
- (29) -C(=NR₁₃)ZR₁₁,
- 15 (30) -OC(Z)NR₈R₉,
- (31) -NR₁₀S(O)_mCF₃,
- (32) -NR₁₀C(Z)OR₁₀,
- (33) 5-(R₁₈)-1,2,4-oxadiazol-3-yl,
- (34) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl or
- 20 (35) azido;

R₇ and R₁₇ are each independently selected from hydrogen or C₁₋₄ alkyl or R₇ and R₁₇ together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR₂₂;

R₈ and R₉ are independently selected from

- (1) hydrogen,
- (2) heterocyclyl,
- (3) heterocyclylalkyl, and
- 30 (4) R₁₁; or

R₈ and R₉ together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR₁₂;

- 8 -

R₁₀ and R₂₀ is each independently selected from hydrogen or C₁₋₄ alkyl;

- R₁₁ is (1) C₁₋₁₀ alkyl,
(2) halo-substituted C₁₋₁₀ alkyl,
(3) C₂₋₁₀ alkenyl,
5 (4) C₂₋₁₀ alkynyl,
(5) C₃₋₇ cycloalkyl,
(6) C₅₋₇ cycloalkenyl,
(7) aryl,
(8) aryl-C₁₋₁₀ alkyl,
10 (9) heteroaryl or
(10) heteroaryl-C₁₋₁₀ alkyl;
- R₁₂ is (1) hydrogen,
(2) -C(Z)R₁₃,
(3) optionally substituted C₁₋₄ alkyl,
15 (4) optionally substituted aryl C₁₋₄ alkyl, or
(5) S(O)₂R₂₅;
- R₁₃ is (1) hydrogen, or
(2) R₂₅;
- R₁₄ and R₂₄ is each independently selected from
20 (1) hydrogen,
(2) alkyl,
(3) nitro or
(4) cyano;
- R₁₅ is (1) hydrogen,
25 (2) cyano,
(3) C₁₋₄ alkyl,
(4) C₃₋₇ cycloalkyl or
(5) aryl;
- R₁₈ and R₁₉ is each independently selected from
30 (1) hydrogen,
(2) C₁₋₄ alkyl,
(3) substituted alkyl, wherein the substituents may be halo,
C₁₋₃ alkoxy, amino, or carboxy,

- 9 -

- (4) optionally substituted aryl, wherein the substituents may be halo, C₁-3 alkoxy, amino, or carboxy;
- (5) optionally substituted arylalkyl, wherein the substituents may be halo, C₁-3 alkoxy, amino, or carboxy, or
- 5 R₁₈ and R₁₉ together denote an oxo or thioxo;
- R₂₁ is (1) R₁₃,
- (2) a pharmaceutically acceptable cation, or
- (3) aroyl, or
- (4) C₁-10 alkanoyl;
- 10 R₂₂ is R₁₀ or C(Z)-C₁-4 alkyl;
- R₂₅ is (1) C₁-10 alkyl,
- (2) C₃-7 cycloalkyl,
- (3) heterocyclyl,
- (4) aryl,
- 15 (5) aryl C₁-10 alkyl,
- (6) heterocyclyl-C₁-10 alkyl,
- (7) heteroaryl or
- (8) heteroaryl C₁-10 alkyl;
- Z is oxygen or sulfur;
- 20 m is 1 or 2;
- n is 1 to 10;
- p is 1 to 10; or
- a pharmaceutically acceptable salt thereof.

In a preferred embodiment, the compounds of formula I are
25 those wherein

- R₁ is 4-pyridyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
- (1) halogen,
- (2) -CN,
- (3) C₁-10 alkyl-, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (4) -O-C₁-10alkyl,
- (5) -S-C₁-10alkyl,

- 10 -

- (6) -NR₈R₉, and
- (7) -NO₂.

- In another preferred embodiment the compounds of formula I are those wherein
- 5 R₂ is phenyl, 1-naphthyl, 2-naphthyl or thiienyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
 - (1) C₁-10 alkyl,
 - (2) R₄, and
- 10 (3) C₁-10 alkyl substituted with up to 5 groups independently selected from R₄.
- In yet another embodiment the compounds of formula I are those wherein
- 15 R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of
 - (1) C₁-3alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (2) -O-C₁-2alkyl,
- 20 (3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,
 - (4) -O-heteroaryl,
 - (5) -NO₂,
 - (6) halogen,
 - (7) -S-CH₃,
 - (8) -S(O)_mC₁-2alkyl,
 - (9) -S(O)_mOR₈.
- 25 In a more preferred embodiment the compounds of formula I are those wherein
- 30 R₁ is 4-pyridyl unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- 11 -

- (1) C₁-10 alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
(2) -O-C₁-10alkyl,
(3) -S-C₁-10alkyl,
5 (4) -NR₈R₉, and
(5) -NO₂;

R₂ is phenyl, 1-naphthyl, 2-naphthyl or thiienyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- 10 (1) C₁-10 alkyl,
(2) R₄, and
(3) C₁-10 alkyl substituted with up to 5 groups independently selected from R₄;

R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of

- 15 (1) C₁-3alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
(2) -O-C₁-2alkyl,
20 (3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,
(4) -O-heteroaryl,
(5) -NO₂,
25 (6) halogen,
(7) -S-CH₃,
(8) -S(O)_mC₁-2alkyl,
(9) -S(O)_mOR₈,


30 R₄ is

- (1) -OR₈,
(2) -NO₂,
(3) halogen
(4) -S(O)_mR₁₁,

- 12 -

- (5) -SR₈,
- (6) -S(O)_mOR₈,
- (7) -S(O)_mNR₈R₉,
- (8) -NR₈R₉,
- 5 (9) -O(CR₁₀R₂₀)_pNR₈R₉,
- (10) -C(O)R₈,
- (11) -CO₂R₈,
- (12) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
- (13) -ZC(O)R₈,
- 10 (14) -CN,
- (15) -C(Z)NR₈R₉,
- (16) NR₁₀C(Z)R₈,
- (17) -C(Z)NR₈OR₉,
- (18) NR₁₀C(Z)NR₈R₉,
- 15 (19) -NR₁₀S(O)_mR₁₁,
- (20) azido.

For the purposes herein of nomenclature, the compounds of formula I are named by their position corresponding to:



20

In another aspect of the present invention, there are provided compounds listed below. These compounds are also especially preferred for the treatment of diabetes:

- 25 (1) 4-(4-fluorophenyl)-2-(4-methoxycarbonylphenyl)-5-(4-pyridyl)imidazole,
- (2) 2-(4-cyanophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (3) 2-(4-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

30

- 13 -

- (4) 4-(4-fluorophenyl)-2-(4-isopropylphenyl)-5-(4-pyridyl)imidazole,
- (5) 2-(4-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 5 (6) 4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)imidazole,
- (7) 4-(4-fluorophenyl)-2-(4-n-heptyphenyl)-5-(4-pyridyl)imidazole,
- 10 (8) 4-(4-fluorophenyl)-2-(4-phenoxyphenyl)-5-(4-pyridyl)imidazole,
- (9) 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-5-(4-pyridyl)imidazole,
- (10) 2-(4-aminophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 15 (11) 2-(3-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (12) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (13) 2-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 20 (14) 4-(4-fluorophenyl)-2-(4-iodophenyl)-5-(4-pyridyl)imidazole,
- (15) 2-(2,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 25 (16) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)imidazole,
- (17) 2-(4-biphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (18) 4-(4-fluorophenyl)-2-(1-naphthyl)-5-(4-pyridyl)imidazole,
- (19) 2-(4-ethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 30 (20) 4-(4-fluorophenyl)-2-(2-naphthyl)-5-(4-pyridyl)imidazole,
- (21) 2-(5-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

- (22) 4-(4-fluorophenyl)-2-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
(23) 2-(4-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
5 (24) 4-(4-fluorophenyl)-2-(4-methylphenyl)-5-(4-pyridyl)imidazole,
(25) 2-(3-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
10 (26) 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(27) 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(28) 2-(3-bromo-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
15 (29) 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(30) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(3-trifluoromethylphenyl)imidazole,
20 (31) 2-(3,4-dimethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(32) 2-(3-chlorophenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
(33) 4-(3-chlorophenyl)-2-(3,4-dichlorophenyl)-5-(4-pyridyl)imidazole,
25 (34) 2-(4-benzyloxyphenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
(35) 2-(3,4-dichlorophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(36) 2-(4-benzyloxyphenyl)-4-phenyl-5-(4-pyridyl)imidazole,
30 (37) 2-(4-bromophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(38) 2-(4-(2-chloro-6-fluorobenzyloxy)phenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(39) 2-(4-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,

- 15 -

- (40) 2-(3-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
(41) 2-(3-chlorophenyl)-4-(4-iodophenyl)-5-(4-pyridyl)imidazole,
5 (42) 2-(4-chlorophenyl)-4-(4-bromophenyl)-5-(4-pyridyl)imidazole,
(43) 2-(4-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
(44) 2-(3-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
10 (45) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(3-methyl-4-pyridyl)imidazole,
(46) 2-(4-chlorophenyl)-4-(2-fluoro-4-trifluoromethylphenyl)-5-(4-pyridyl)imidazole,
15 (47) 2-(4-chlorophenyl)-4-(2-phenoxyphenyl)-5-(4-pyridyl)imidazole,
(48) 4-(3-bromophenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
(49) 4-(3-bromo-4-methoxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
20 (50) 2-(4-chlorophenyl)-4-(2-ethoxyphenyl)-5-(4-pyridyl)imidazole, and
(51) 2-(4-Azidophenyl)-4-(3-iodophenyl)-5-(4-pyridyl)imidazole.
25

The invention is described herein in detail using the terms defined below unless otherwise specified.

"Halogen" includes fluorine, chlorine, bromine and iodine.

The term "alkyl" refers to a monovalent alkane

- 30 (hydrocarbon)-derived radical containing the designated number of carbon atoms. It may be straight or branched. Examples include methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, sec-butyl, isopentyl and t-butyl.

- 16 -

The term "cycloalkyl" refers to a cyclized alkane (hydrocarbon)-derived radical containing the designated number of carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

5 The term "alkenyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) carbon-carbon double bonds may be present. Examples of alkenyl groups
10 include ethenyl, propenyl, butenyl and isobutenyl.

15 The term "alkynyl" refers to a hydrocarbon radical, straight or branched, containing the designated number of carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Examples of alkynyl groups include ethynyl, propynyl and butynyl.

Aryl refers to aromatic rings including phenyl and naphthyl.

20 The term "heteroaryl" (on its own or in any combination, such as "heteroaryloxy") represents a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O and S, such as, but not limited to pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, imidazolyl, thiazolyl, thiadiazolyl, tetrazolyl, triazolyl, oxadiazolyl, oxazolyl, imidazolidinyl, pyrazolyl, isoxazolyl, benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl,
25 2,3-dihydrobenzofuranyl, quinolinyl, isoquinolinyl, benzotriazolyl, benzoxazolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, purinyl, fuopyridine and thienopyridine, tetrahydrobenzothiazolyl, 5,6,7,8-tetrahydroquinolinyl, 2,3-cyclopentenopyridyl, 4,5,6,7-tetrahydroindolyl, 5,6,7,8-tetrahydroisoquinolyl, and 5,6,7,8-tetrahydroquinoxalinyl.

30 "Heterocyclic" (on its own or in any combination, such as "heterocyclalkyl") represents a saturated or wholly or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O and S. Examples of heterocycls are piperidinyl, morpholinyl,

pyrrolidinyl, tetrahydrofuranyl, tetrahydroimidazo[4,5-c]pyridine, imidazolinyl, piperazinyl, pyrazolindinyl and the like.

The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.

The compounds of the present invention may contain one or more asymmetric carbon atoms and may occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included within the scope of the present invention.

Throughout the instant application, the following abbreviations are used with the following meanings:

20	Bu	butyl
	Bn	benzyl
	BOC, Boc	t-butyloxycarbonyl
	BOP	Benzotriazol-1-yloxy tris(dimethylamino)-phosphonium hexafluorophosphate
25	CBZ, Cbz	Benzyloxycarbonyl
	DCC	Dicyclohexylcarbodiimide
	DCM	dichloromethane
	DIEA	diisopropylethylamine
	DMF	N,N-dimethylformamide
30	DMAP	4-Dimethylaminopyridine
	DSC	N,N'-disuccinimidyl carbonate
	DTT	dithiothreitol
	EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

	Et	ethyl
	EtOAc	ethyl acetate
	EtOH	ethanol
	eq.	equivalent(s)
5	FAB-MS	Fast atom bombardment-mass spectroscopy
	HBGF	hemoglobin growth factor
	HOAc	acetic acid
	HPLC	High pressure liquid chromatography
	HOBT, HOBt	Hydroxybenztriazole
10	HS	human serum
	KHMDS	Potassium bis(trimethylsilyl)amide
	LAH	Lithium aluminum hydride
	LHMDS	Lithium bis(trimethylsilyl)amide
	Me	methyl
15	MHz	Megahertz
	MPLC	Medium pressure liquid chromatography
	NMM	N-Methylmorpholine
	NMR	Nuclear Magnetic Resonance
	PBS	phosphate buffer saline
20	Ph	phenyl
	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
	TLC	Thin layer chromatography
	TMS	Tetramethylsilane
25		

The pharmaceutically acceptable salts of the compounds of formula I include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of formula I formed e.g. from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric,

toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

- The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
- This invention relates to a method of inhibiting the action of glucagon at its receptors thereby reducing the rate of gluconeogenesis and the concentration of glucose in plasma. Thus, compounds of formula I can be used in the prophylaxis or treatment of disease states in mammals mediated by elevated levels of glucagon.
- Examples of such disease states include diabetes, obesity, hypertension, and cachexia and the like.

- The compounds of formula I are normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. This invention, therefore, also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier employed may be, for example, solid or liquid. Solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier may include time delay material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.

- The compounds of formula I are administered in conventional dosage forms prepared by combining a compound of formula I with standard pharmaceutical carriers according to conventional procedures. The compounds of formula I may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or 5 they may be incorporated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incorporated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain 10 at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will 15 be obtained.

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a 20 sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be 25 coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered 30 parenterally, for example intravenously, intramuscularly, intradermally or subcutaneously. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary

conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the

- 5 extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a
- 10 solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

- The compounds of formula I may also be administered topically in the form of a liquid, solid or semi-solid. Liquids include
- 15 solutions, suspensions and emulsions. Solids include powders, poultices and the like. Semi-solids include creams, ointments, gels and the like.

- Drops according to the present invention may comprise sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.

- Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

- 30 Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous liquid, with the aid of suitable machinery, with a

greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or macrogels. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicas, and other ingredients such as lanolin may also be included.

Compounds of the present invention may also be administered intranasally as, for example, liquid drops or spray; by intranasal or oral inhalation; rectally; trasdermally; or vaginally.

The amount of a compound of formula I, for the methods of use disclosed herein, vary with the compound chosen, the mode of administration, the nature and severity of the condition being treated, and other factors left to the discretion of the physician. A representative dosing regimen for treating diabetes mellitus and/or hyperglycemia may involve administering a compound of formula I at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.07 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

Compounds similar to Formula I have been described previously as cytokine inhibitors (WO93/14081; WO95/03297), antiinflammatory agents (WO96/03387), and protein kinase inhibitors (WO96/18626). None of these publications describe or claim treatment of diabetes by antagonism of the glucagon receptor.

Compounds of the present invention may be prepared by several general synthetic methods as described in, for example, M. R. Grimmett, *Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds*, A. R.


- 23 -

Katritzky and C. W. Rees, eds., Vol. 5, Pergamon Press, Oxford, 1984, pp. 457-498. The compounds of the present invention can be prepared by procedures illustrated in the accompanying schemes. The three general methods for preparation of the imidazole nucleus are outlined in Schemes 5 1 and 2.

In the first method (Scheme 1), a suitably protected alcohol (1) (e.g., when R₁ is 4-pyridyl, (1) is 4-(t-butyldimethylsilyloxy)methylpyridine), is deprotonated with a strong base such as lithium diisopropyl amide or n-butyl lithium and the 10 resulting anion is reacted with an appropriate N,O-dimethylhydroxamide (2) to give a protected α -hydroxy ketone (3). The protected α -hydroxy ketone is then condensed with a suitably functionalized aldehyde (4) in the presence of copper(II) acetate and ammonium acetate in acetic acid to form the desired compound (5).

15

Scheme 1.




In the second method (Scheme 2), an heteroarylmethane (6) (e.g., when R₁ is 4-pyridyl, (6) is 4-picoline) is deprotonated with a 20 strong base such as lithium diisopropyl amide or n-butyl lithium and the resulting anion is reacted with N,O-dimethylhydroxamide (2) to give a ketone (7). The dione (8) is obtained by selenium dioxide oxidation of

- 24 -

the ketone (7) and then condensed with a suitably functionalized aldehyde (4) in the presence of ammonium acetate in acetic acid to form the desired imidazole (5).

Scheme 2.



5

In the various synthetic methods described above, protection and deprotection of functional groups such as hydroxyl and amino groups may be required. The selection of the appropriate protecting groups, and
10 methods for introducing and removing the protecting groups are within the knowledge of one skilled in the art, and are also described in standard reference books such as Greene and Wuts, Protective Groups in Organic Synthesis, 2d Ed., John Wiley & Sons, Inc., 1991.


15 The following examples are provided to more fully illustrate the invention, and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLE 1

20

2-(4-Bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole

- 25 -



Step A: 4-t-Butydimethylsilyloxyethylpyridine

- 5 To a solution of 4-pyridylcarbinol (50.3 g, 0.46 mol) in methylene chloride (250 mL) under a dry nitrogen atmosphere was added triethylamine (97 mL, 0.69 mol). To this mixture was added dropwise tert-butyl-dimethylsilyl chloride (83.7 g, 0.555 mol) with cooling ($T = 34^\circ\text{C}$). The reaction mixture was stirred overnight at room temperature.. The slurry was
10 then filtered and the solvent removed by rotovaporation. The residue was suspended in toluene and filtered and the solvent removed by rotovaporation. The residue was suspended in diethyl ether and filtered and the solvent removed by rotovaporation. The same process was repeated with hexanes to yield 4-t-butydimethylsilyloxyethylpyridine as a brown oil.

15

Step B: 4-Fluoro-N-methoxy-N-methyl-benzamide

- To a stirred, cooled suspension of N,O-dimethylhydroxylamine hydrochloride (67.7 g, 0.69 mol) in methylene chloride (750 mL) at 0°C was added dropwise triethylamine (211 mL, 1.51 mol). To this mixture was added dropwise 4-fluorobenzoyl chloride (100 g, 0.63 mol) over a 35 min period.
20 After the addition was complete, the reaction mixture was stirred at room temperature overnight. A fine precipitate formed. The reaction mixture was filtered and the filtrate added to water (2 L). The organic phase was separated and washed successively with water and saturated salt solution. After drying
25 the solution over anhydrous magnesium sulfate, the solvent was removed by rotovaporation. The residue was azeotroped with toluene and the solvent removed by rotovaporation and pumping under high vacuum to yield the title compound as a golden yellow oil.

Step C. 4-Pyridyl-t-butydimethylsilyloxy methyl 4-fluorophenyl ketone

Into a 2 L 3-necked round bottom flask fitted with a thermometer, dry nitrogen gas inlet, addition funnel and mechanical stirrer was added

5 diisopropylamine (65 mL, 0.46 mol) in THF (120 mL). Cooled to -20 °C with a isopropyl alcohol/ dry ice bath and added a solution of n-butyllithium in hexanes (210 mL of a 2.5 M solution, 0.53 mol). Stirred at -15 °C for 30 min, then cooled to -20 °C. Added 4-t-butydimethylsilyloxy methylpyridine (98.2 g, 0.44 mol) neat over a 30 min period. Let stir for 45 min at -20 °C. To this

10 mixture was added a solution of 4-fluoro-N-methoxy-N-methyl-benzamide (84.5 g, 0.46 mol) in THF (90 mL) over a 30 min period. The dark solution was stirred at 0 °C for 1 h, then warmed slowly to room temperature for 30 min. The reaction was poured into water (500 mL) containing ammonium chloride (100 g). After stirring for 10 min at room temperature, the solution was

15 extracted with ethyl acetate (3 times). The combined organic extracts were washed successively with water and saturated salt solution. The combined aqueous layers were extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed by rotovaporation. The residue was purified

20 by flash column chromatography on silica gel eluted with 15-50% ethyl acetate in hexanes (17 L in total). The solvent was removed by rotovaporation to yield the title compound as an amber oil (120.4 g, 74% yield).

Step D: 2-(4-Bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole

25 To a solution of 4-pyridyl-t-butydimethylsilyloxy methyl 4-fluorophenyl ketone from Step C (100 mg, 0.29 mmol) in acetic acid (2 mL) was added copper(II) acetate (105.1 mg, 0.58 mmol) followed by solid ammonium acetate (222 mg, 2.89 mmol) and 4-bromobenzaldehyde (66.8 mg, 0.36 mmol). The reaction was stirred at 100 °C for 2.5 h and then cooled to 0 °C. Ice (1.5 g) and ethyl acetate (3 mL) were added. Ammonium hydroxide solution (4 mL) was added dropwise. Saturated ammonium chloride solution (1.5 mL) was added and the reaction mixture stirred at room temperature for 30 min. The phases were separated and the aqueous phase extracted with ethyl acetate (2 times). The combined organic phases were successively washed

- 27 -

with water and saturated salt solution and dried over anhydrous sodium sulfate. The solvent was removed by rotovaporation and the residue purified by flash column chromatography on silica gel eluted with 1-2% methanol in methylene chloride. The title compound was homogeneous by TLC and isolated as a
5 yellow solid (67 mg, 59% yield, mp. 274-5 °C), mass spectrum (CI) m/e = 394, 396 (M+1)⁺.

The following compounds were prepared by methods analogous to those described in Example 1 except the appropriately substituted N-methoxy-N-
10 methylbenzamide and substituted benzaldehyde was used in place of 4-fluoro-N-methoxy-N-methylbenzamide and 4-bromobenzaldehyde, respectively.

- 15 4-(4-fluorophenyl)-2-(4-methoxycarbonylphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 374 (M+1)⁺.
- 20 2-(4-cyanophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 341 (M+1)⁺.
 2-(4-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 422 (M+1)⁺.
- 25 4-(4-fluorophenyl)-2-(4-isopropylphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 358 (M+1)⁺.
- 30 4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 361 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(4-n-heptyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 430 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(4-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 408 (M+1)⁺.
 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 346 (M+1)⁺.

- 2-(3-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 394, 396 (M+1)⁺.
- 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 350 (M+1)⁺.
- 5 2-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 384, 386 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(4-iodophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 442 (M+1)⁺.
- 10 2-(2,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 384, 386 (M+1)⁺.
- 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)imidazole, mass spectrum (CI) m/e = 384 (M+1)⁺.
- 15 2-(4-biphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 392 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(1-naphthyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366 (M+1)⁺.
- 20 2-(4-ethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 344 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(2-naphthyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366 (M+1)⁺.
- 25 2-(5-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 400, 402 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 408 (M+1)⁺.
- 30 2-(4-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 400, 402 (M+1)⁺.
- 4-(4-fluorophenyl)-2-(4-methylphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 330 (M+1)⁺.
- 2-(3-benzylloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 422 (M+1)⁺.

- 29 -

- 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 350 (M+1)⁺.
- 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 352 (M+1)⁺.
- 5 2-(3-bromo-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 412, 414 (M+1)⁺.
- 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 368 (M+1)⁺.
- 10 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(3-trifluoromethylphenyl)imidazole, mass spectrum (CI) m/e = 384 (M+1)⁺.
- 2-(3,4-dimethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 344 (M+1)⁺.
- 15 2-(3-chlorophenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366 (M+1)⁺.
- 4-(3-chlorophenyl)-2-(3,4-dichlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 400, 402 (M+1)⁺.
- 20 2-(4-benzyloxyphenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 400, 402 (M+1)⁺.
- 2-(3,4-dichlorophenyl)-4-phenyl-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366, 368 (M+1)⁺.
- 25 2-(4-benzyloxyphenyl)-4-phenyl-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 404 (M+1)⁺.
- 2-(4-bromophenyl)-4-phenyl-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 376, 378 (M+1)⁺.
- 2-(4-(2-chloro-6-fluorobenzyloxy)phenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 474 (M+1)⁺.
- 2-(4-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366 (M+1)⁺.
- 30 2-(3-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 366 (M+1)⁺.
- 2-(3-chlorophenyl)-4-(4-iodophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 458 (M+1)⁺.

- 30 -

2-(4-chlorophenyl)-4-(4-bromophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 410, 412 (M+1)⁺.

2-(4-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole, mass spectrum (CI) m/e = 400 (M+1)⁺.

5 2-(3-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole, mass spectrum (CI) m/e = 400 (M+1)⁺.

2-(4-chlorophenyl)-4-(2-phenoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 424 (M+1)⁺.


10 4-(3-bromo-4-methoxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 440, 442 (M+1)⁺.

2-(4-chlorophenyl)-4-(2-ethoxyphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 376 (M+1)⁺.

15

EXAMPLE 2

2-(4-Aminophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole



20

A solution of 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (prepared according to the method described in Example 1, 25 mg, 0.07 mmol) in ethanol (2 mL) and ethyl acetate (1 mL) containing 10% palladium on carbon (12 mg) was stirred under a hydrogen atmosphere (1 atm) for 4 h. The contents of the flask were centrifuged to remove the catalyst. The solvent was removed and the catalyst washed and centrifuged with fresh ethyl acetate (3 times). The combined organic phases were rotoevaporated and the residue purified by flash column chromatography on silica gel eluted with 0-

- 31 -


5% methanol in methylene chloride. The desired fractions were collected, combined and the solvent removed by rotovaporation to yield the title compound as a yellow solid (20 mg, 88% yield), mass spectrum (CI) m/e = 331 (M+1)⁺.

5

EXAMPLE 3

4-(3-Bromophenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole

10



Step A: 3-Bromo-N-methoxy-N-methylbenzamide.

To a mixture of N,O-dimethylhydroxylamine hydrochloride (4.8 g, 50 mmol) in methylene chloride (50 mL) was added dropwise triethylamine (11.1 g, 109 mmol). After cooling to 0 °C, a solution of 3-bromobenzoyl chloride (10 g, 45.6 mmol) in methylene chloride (10 mL) was added dropwise. The reaction mixture was stirred overnight at room temperature. The contents of the reaction flask were filtered through a pad of celite filter aid wet with diethyl ether. The filter pad was subsequently washed twice with fresh diethyl ether. The solvent of the combined organic phases was removed by rotovaporation. The residue was purified by flash column chromatography on silica gel eluted with 0-50% ethyl acetate in hexanes. The title compound was isolated as a thick, colorless gum (9.46 g, 85% yield).

25

Step B: 3-Bromophenyl 4-pyridylmethyl ketone

To a solution of LDA (prepare from diisopropylamine (2.17 g, 21.5 mmol) in THF (6 mL) and n-butyllithium (9.8 mL of a 2.5M solution in

- 32 -

hexanes) at -78 °C was added dropwise a solution of 4-picoline (1.82 g, 19.5 mmol) in THF (6 mL). The reaction mixture was stirred at -78 to -30 °C for 45 min. The reaction mixture was then cooled to -78 °C and a solution of 3-bromo-N-methoxy-N-methylbenzamide (5 g, 20.5 mmol) in THF (6 mL) was
5 added dropwise. The reaction mixture was stirred for 1 h with gradual warming to -30 °C. The reaction was then quenched with saturated ammonium chloride solution (5 mL). The phases were separated and the aqueous layer was extracted with ethyl acetate (2 times). The combined organic phases were washed successively with water and saturated salt solution and dried over
10 anhydrous sodium sulfate. The solvent was removed by rotovaporation and the crude product purified by flash column chromatography on silica gel eluted with 0-50% ethyl acetate in hexanes. The title compound was isolated as a cream-colored solid (785 mg, 14 % yield), mass spectrum (CI) m/e = 276, 278 (M+1)⁺.

15

Step C: 1-(3-Bromophenyl)-2-(4-pyridyl)-ethane-1,2-dione

To a solution of 3-bromophenyl 4-pyridylmethyl ketone (prepared according to Step B, 1.978 g, 7.17 mmol) in acetic acid (50 mL) was
20 added selenium dioxide powder (796 mg, 7.17 mmol). The reaction mixture was stirred at 100 °C for 40 min. The reaction was then cooled to 0 °C and saturated solution of potassium carbonate was added until the pH ~ 9. The mixture was extracted with ethyl acetate (2 times) and the combined organic phases washed successively with water and saturated salt solution and dried
25 over anhydrous sodium sulfate. The solvent was removed by rotovaporation and the crude product purified by flash column chromatography on silica gel eluted with 10-50% ethyl acetate in hexanes. The title compound was isolated as a pale yellow solid (807 mg, 39% yield).

30

Step D: 4-(3-Bromophenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole

To a solution of 1-(3-bromophenyl)-2-(4-pyridyl)-ethane-1,2-dione from Step C (400 mg, 1.38 mmol) in acetic acid (10 mL) was added ammonium acetate (1.06 g, 13.8 mmol) and 4-chlorobenzaldehyde (242 mg,

- 33 -

1.72 mmol). The reaction mixture was stirred at 100 °C for 3 h. The reaction was cooled to 0 °C and ice and ethyl acetate were added. Concentrated ammonium hydroxide solution was added to pH ~10. The layers were separated and the aqueous phase extracted with ethyl acetate (2 times). The
 5 organic phases were combined and washed successively with water and saturated salt solution and dried over anhydrous sodium sulfate. The solvent was removed by rotovaporation and the crude product purified by flash column chromatography on silica gel eluted with 0-3% methanol in methylene chloride. The title compound was isolated as a pale yellow-orange solid (270 mg, 48% yield), mass spectrum (CI) m/e = 410, 412 (M+1)+.

10

The following compounds were prepared by methods analogous to those described in Example 3 except the appropriately substituted N-methoxy-N-methylbenzamide and substituted 4-picoline was used in place of 4-fluoro-N-methoxy-N-methylbenzamide and 4-picoline, respectively.

15


20 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(3-methyl-4-pyridyl)imidazole, mass spectrum (CI) m/e = 364 (M+1)+.

25 2-(4-chlorophenyl)-4-(2-fluoro-4-trifluoromethylphenyl)-5-(4-pyridyl)imidazole, mass spectrum (CI) m/e = 418 (M+1)+.

25

EXAMPLE 4

2-(4-Azidophenyl)-4-(3-iodophenyl)-5-(4-pyridyl)imidazole



Step A: N-Methoxy-N-methyl-3-iodobenzamide

EDC (6.91 g, 36 mmole) was added to a cooled solution of 3-
5 iodobenzoic acid (7.41 g, 30 mmol), N-methylmorpholine (7.61 g, 8.27 mL, 75
mmol), N-methoxy-methylamine hydrochloride (3.53 g, 36 mmol) in
methylene chloride (100 mL) at 0 °C. The mixture was stirred at room
temperature for 3 days. Water was added and the phase separated. The
aqueous phase was extracted twice with methylene chloride. The combined
10 organic phases were washed successively with water (2X) and saturated salt
solution and dried over anhydrous sodium sulfate. The solvent was removed
by rotoevaporation and product was purified by flash column chromatography
on silica gel eluted with 17-28% ethyl acetate in hexanes to give a colorless oil
(7.67 g, 88% yield); homogeneous by TLC, mass spectrum (CI) m/e 292.1
(M+1)⁺.

15

Step B: 3-Iodophenyl 4-pyridylmethyl ketone

To a solution of lithium diisopropylamide (21 mmol) prepared
from diisopropylamine (2.12 g, 2.75 mL) in THF (40 mL) and n-butyllithium
(8.4 mL of a 2.5 M solution in hexanes)) at -45 °C was added dropwise 4-
20 picoline (1.96 g, 2.04 mL). The yellow/orange reaction mixture was stirred 1
hr at -20 to -45 °C. A solution of N-methoxy-N-methyl-3-iodobenzamide from
Step A (3.015 g, 10.4 mmol) in THF (10 mL) was added dropwise at -30 °C.
The stirred reaction mixture was allowed to warm to 5 °C over 4 h. The
reaction was quenched by the addition of a 1/2 saturated solution of ammonium
25 chloride (30 mL) at 0 to 5 °C. The phases were separated and the aqueous
phase extracted with ethyl acetate (3 times). The combined organic layers were
successively washed with water and saturated salt solution and dried over
anhydrous sodium sulfate. The solvent was removed by rotoevaporation and
the residue purified by flash column chromatography on silica gel eluted with
30 20-65% ethyl acetate in hexanes to yield the title compound as a yellow solid
(2.15 g, 64% yield), mass spectrum (CI) m/e 324.1 (M+1)⁺.

Step C: 1-(3-Iodophenyl)-2-(4-pyridyl)ethane-1,2-dione

- 35 -

- A mixture of 3-iodophenyl 4-pyridylmethyl ketone from Step B (3.09 g, 9.57 mmol) and selenium dioxide powder (1.062 g, 9.57 mmol) in degassed glacial acetic acid (22 mL) was heated to 90 °C for 30 min in the dark. The reaction mixture was cooled to 0 °C and ethyl acetate (30 mL) was
- 5 added. A solution of potassium carbonate (26 g) in water (140 mL) was carefully added dropwise to the reaction mixture until the pH reached ~8. The organic phase was separated and the aqueous phase was treated with additional potassium carbonate solution until pH 10. The aqueous phase was then extracted with ethyl acetate (3 times). The combined organic phases were
- 10 washed successively with water and saturated salt solution and dried over anhydrous sodium sulfate. The solvent was removed by rotovaporation and the residue purified by flash column chromatography on silica gel eluted with 20-50% ethyl acetate in hexanes in the dark to give the title compound as a yellow solid (1.3 g, 40% yield), mass spectrum (CI) m/e 338.1 (M+1)⁺.
- 15 Step D: 2-(4-Azidophenyl)-4-(3-iodophenyl)-5-(4-pyridyl)imidazole
[Note: It is important to perform this reaction and all subsequent manipulations including drying, rotovaporation and column chromatography as much in the dark as possible. The product is very light sensitive.]
- 20 To a solution of 1-(3-iodophenyl)-2-(4-pyridyl)ethane-1,2-dione from Step C (1.3 g, 3.86 mmol) in glacial acetic acid (10 mL) under dry nitrogen atmosphere was added ammonium acetate (3.0 g, 39 mmol) followed by 4-azidobenzaldehyde (681 mg, 4.63 mmol). The reaction mixture was heated for 2 h. After cooling to 0 °C, ammonium hydroxide solution was
- 25 added until pH 8 was obtained. The phases were separated. The aqueous phase (adjusted to pH 10 with more ammonium hydroxide solution) was extracted with ethyl acetate (3 times). The combined organic layers were washed successively with water and saturated salt solution and dried over anhydrous sodium sulfate. The solvent was removed by rotovaporation and
- 30 the residue purified by flash column chromatography on silica gel eluted with 25-80% ethyl acetate in hexanes to yield the title compound as a pale brown glass (579 mg, 33% yield), mass spectrum (CI) m/e 465.1 (M+1)⁺.

BIOLOGICAL ASSAYS

The ability of compounds of the present invention to inhibit the binding of glucagon and the synthesis or the activity of cytokines can be determined by the following *in vitro* assays.

5 **125I-Glucagon Binding Screen with CHO/hGLUR Cells**

The reagents are prepared as follows:

1M o-Phenanthroline (Aldrich #32,005-6, MW 198.23) (prepare fresh): 198.2 mg/ml ethanol

10

0.5M DTT (Sigma #D-9779, MW 154.2) (prepare fresh).

15 Protease Inhibitor Mix(1000X): 5 mg leupeptin + 10 mg benzamidine + 40 mg bacitracin + 5 mg soybean trypsin inhibitor per ml DMSO. Store aliquots at -20 °C.

20 250 µM Human Glucagon (Peninsula #7165,MW 3480.62): Solubilize 0.5 mg vial in 575 µl 0.1N acetic acid.Store in aliquots at -20 °C. Thus, 1 µl yields 1 µM final concentration in assay for non-specific binding.

25

Assay Buffer: 20 mM Tris, pH 7.8; 1 mM DTT; 3 mM o-phenanthroline.

Assay Buffer w/ 0.1% BSA (for dilution of label only, therefore 0.01% final in assay): 10 µl 10% BSA (heat-inactivated) + 990 µl assay buffer

25

125I-Glucagon (NEN #NEX-207, receptor-grade, 2200 Ci/mmol): Dilute to 50,000 cpm/25 µl in assay buffer w/ BSA.Thus, ~50 pM final concentration in assay.

30 Harvesting of CHO/hGLUR Cells for Assay:

1. Remove media from confluent flask then rinse once each with PBS (Ca,Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).

- 37 -

2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for ~4 min. at 37 °C.
 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
 - 5 4. Resuspend pellet in assay buffer (no BSA) at 75000 cells per 100 µL.
- Alternatively, membrane preparations from CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of membrane preparation is determined on a per batch basis.
- 10

The determination of inhibition of glucagon binding is carried out by measuring the reduction of I^{125} -glucagon binding in the presence of compounds of Formula I. The assay is carried out in a 96-well box. The following reagents are combined:


	<u>Assay Buffer</u>	<u>Compound /Vehicle</u>	<u>250uM Glucagon</u>	<u>$125I$- Glucagon</u>	<u>CHO/hGLUR Cells</u>
20 Total Binding	120 µL	--/5 µL	--	25 µL	100 µL
+compound	120 µL	5 µL/--	--	25 µL	100 µL
25 NSB	120 µL	--/5 µL	1 µL	25 µL	100 µL

NSB:non specific binding

30 The box is incubated for 60 min. at 22 °C on a shaker at 275 rpm. The wells are filtered over pre-soaked (0.5% polyethylimine(PEI)) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20 mM Tris, pH 7.8 buffer. Count filters in Gamma-scintillation counter.

WHAT IS CLAIMED IS:

1. A method of treating glucagon mediated disease in a mammal in need of such treatment, which comprises administering to
 5 said mammal an effective amount of a glucagon antagonist of formula (I):



wherein

- 10 R₁ is 4-pyridyl, 4-pyrimidinyl or 4-quinolyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
 (1) halogen,
 (2) -CN,
 (3) C₁-10 alkyl-, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 (4) -O-C₁-10alkyl,
 (5) -S-C₁-10alkyl,
 (6) -NR₈R₉, and
 15 (7) -NO₂;
 R₂ is phenyl, 1-naphthyl, 2-naphthyl or heteroaryl which is unsubstituted or substituted with one, two or three substituents each of which is independently selected from the group consisting of
 (1) C₁-10 alkyl,
 (2) R₄, and
 (3) C₁-10 alkyl substituted with up to 5 groups independently selected from R₄;
 20 R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of
 25

- (1) C₁₋₃alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (2) -O-C₁₋₂alkyl,
- (3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,
- (4) -O-heteroaryl,
- (5) -NO₂,
- (6) halogen,
- (7) -S-CH₃,
- (8) -S(O)_mC₁₋₂alkyl,
- (9) -S(O)_mOR₈,
- (10) -S(O)_mNR₈R₉,
- (11) -O(CR₁₀R₂₀)_pNR₈R₉,
- (12) -C(O)C₁₋₂alkyl,
- (13) -CO₂C₁₋₂alkyl,
- (14) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
- (15) -ZC(O)R₈,
- (16) -CN,
- (17) -C(Z)NR₈R₉,
- (18) amino,
- (19) NR₁₀C(Z)R₈,
- (20) -C(Z)NR₈OR₉,
- (21) NR₁₀C(Z)NR₈R₉,
- (22) -NR₁₀S(O)_mR₁₁,
- (23) -C(=NOR₂₁)R₈,
- (24) -NR₁₀C(=NR₁₅)SR₁₁,
- (25) -NR₁₀C(=NR₁₅)NR₈R₉,
- (26) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
- (27) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,
- (28) -NR₁₀C(O)C(O)NR₈R₉,
- (29) -NR₁₀C(O)C(O)OR₁₀,
- (30) -NR₁₀S(O)_mNR₇R₁₇,

- 40 -

- (31) -C(=NR₁₃)NR₈R₉,
 - (32) -C(=NOR₁₃)NR₈R₉,
 - (33) -C(=NR₁₃)ZR₁₁,
 - (34) -OC(Z)NR₈R₉,
 - (35) -NR₁₀S(O)_mCF₃,
 - (36) -NR₁₀C(Z)OR₁₀,
 - (37) 5-(R₁₈)-1,2,4-oxadiazol-3-yl or
 - (38) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl;

R₄ is

- 10 (1) -OR₈,
 (2) -NO₂,
 (3) halogen
 (4) -S(O)_mR₁₁,
 (5) -SR₈,
 15 (6) -S(O)_mOR₈,
 (7) -S(O)_mNR₈R₉,
 (8) -NR₈R₉,
 (9) -O(CR₁₀R₂₀)_pNR₈R₉,
 (10) -C(O)R₈,
 20 (11) -CO₂R₈,
 (12) -CO₂(CR₁₀R₂₀)_nCONR₈R₉,
 (13) -ZC(O)R₈,
 (14) -CN,
 (15) -C(Z)NR₈R₉,
 25 (16) NR₁₀C(Z)R₈,
 (17) -C(Z)NR₈OR₉,
 (18) NR₁₀C(Z)NR₈R₉,
 (19) -NR₁₀S(O)_mR₁₁,
 (20) -C(=NOR₂₁)R₈,
 30 (21) -NR₁₀C(=NR₁₅)SR₁₁,
 (22) -NR₁₀C(=NR₁₅)NR₈R₉,
 (23) -NR₁₀C(=CR₁₄R₂₄)SR₁₁,
 (24) -NR₁₀C(=CR₁₄R₂₄)NR₈R₉,
 (25) -NR₁₀C(O)C(O)NR₈R₉,

- 41 -

- (26) -NR₁₀C(O)C(O)OR₁₀,
(27) -C(=NR₁₃)NR₈R₉,
(28) -C(=NOR₁₃)NR₈R₉,
(29) -C(=NR₁₃)ZR₁₁,
5 (30) -OC(Z)NR₈R₉,
(31) -NR₁₀S(O)_mCF₃,
(32) -NR₁₀C(Z)OR₁₀,
(33) 5-(R₁₈)-1,2,4-oxadiazol-3-yl,
10 (34) 4-(R₁₂)-5-(R₁₈R₁₉)-4,5-dihydro-1,2,4-oxadiazol-3-yl or
(35) azido;

R₇ and R₁₇ are each independently selected from hydrogen or C₁-4 alkyl or
R₇ and R₁₇ together with the nitrogen to which they are attached
form a heterocyclic ring of 5 to 7 members which ring optionally
contains an additional heteroatom selected from oxygen, sulfur or
15 NR₂₂;

R₈ and R₉ are independently selected from

- (1) hydrogen,
(2) heterocyclyl,
(3) heterocyclylalkyl, and
20 (4) R₁₁; or

R₈ and R₉ together with the nitrogen to which they are attached form a
heterocyclic ring of 5 to 7 members which ring optionally
contains an additional heteroatom selected from oxygen, sulfur or
NR₁₂;

25 R₁₀ and R₂₀ is each independently selected from hydrogen or C₁-4 alkyl;

- R₁₁ is (1) C₁-10 alkyl,
(2) halo-substituted C₁-10 alkyl,
(3) C₂-10 alkenyl,
(4) C₂-10 alkynyl,
30 (5) C₃-7 cycloalkyl,
(6) C₅-7 cycloalkenyl,
(7) aryl,
(8) aryl-C₁-10 alkyl,
(9) heteroaryl or

- 42 -

- R₁₂ is (10) heteroaryl-C₁-10 alkyl;
 (1) hydrogen,
 (2) -C(Z)R₁₃,
 (3) optionally substituted C₁-4 alkyl,
5 (4) optionally substituted aryl C₁-4 alkyl, or
 (5) S(O)₂R₂₅;
- R₁₃ is (1) hydrogen, or
 (2) R₂₅;
- R₁₄ and R₂₄ is each independently selected from
10 (1) hydrogen,
 (2) alkyl,
 (3) nitro or
 (4) cyano;
- R₁₅ is (1) hydrogen,
15 (2) cyano,
 (3) C₁-4 alkyl,
 (4) C₃-7 cycloalkyl or
 (5) aryl;
- R₁₈ and R₁₉ is each independently selected from
20 (1) hydrogen,
 (2) C₁-4 alkyl,
 (3) substituted alkyl, wherein the substituents may be halo,
 C₁-3 alkoxy, amino, or carboxy,
 (4) optionally substituted aryl, wherein the substituents may
25 be halo, C₁-3 alkoxy, amino, or carboxy,
 (5) optionally substituted arylalkyl, wherein the substituents
 may be halo, C₁-3 alkoxy, amino, or carboxy, or
- R₁₈ and R₁₉ together denote an oxo or thioxo;
- R₂₁ is (1) R₁₃,
30 (2) a pharmaceutically acceptable cation, or
 (3) aroyl, or
 (4) C₁-10 alkanoyl;
- R₂₂ is R₁₀ or C(Z)-C₁-4 alkyl;
- R₂₅ is (1) C₁-10 alkyl,

- (2) C₃-7 cycloalkyl,
 (3) heterocyclyl,
 (4) aryl,
 (5) aryl C₁-10 alkyl,
 5 (6) heterocyclyl-C₁-10 alkyl,
 (7) heteroaryl or
 (8) heteroaryl C₁-10 alkyl;
 Z is oxygen or sulfur;
 m is 1 or 2;
 10 n is 1 to 10;
 p is 1 to 10; or
 a pharmaceutically acceptable salt thereof.

2. The method of Claim 1 wherein said glucagon

15 antagonist is a compound of formula I wherein

R₁ is 4-pyridyl which is unsubstituted or substituted with one or two

substituents each of which is independently selected from the group consisting of

- (1) halogen,
 - (2) -CN,
 - (3) C₁-10 alkyl-, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
 - (4) -O-C₁-10alkyl,
 - (5) -S-C₁-10alkyl,
 - (6) -NR₈R₉, and
 - (7) -NO₂.

3. The method of Claim 1 wherein said glucagon

antagonist is a compound of formula I wherein

30 R₂ is phenyl, 1-naphthyl, 2-naphthyl or thienyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- (1) C₁-10 alkyl,
 (2) R₄ and

- 44 -

(3) C₁-10 alkyl substituted with up to 5 groups independently selected from R₄.

4. The method of Claim 1 wherein said glucagon antagonist is a compound of formula I wherein R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of
- 10 (1) C₁-3alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (2) -O-C₁-2alkyl,
- (3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,
- 15 (4) -O-heteroaryl,
- (5) -NO₂,
- (6) halogen,
- (7) -S-CH₃,
- 20 (8) -S(O)_mC₁-2alkyl,
- (9) -S(O)_mOR₈.

5. The method of Claim 1 wherein said glucagon antagonist is a compound of formula I wherein R₁ is 4-pyridyl unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of
- 25 (1) C₁-10 alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
- (2) -O-C₁-10alkyl,
- (3) -S-C₁-10alkyl,
- (4) -NR₈R₉, and
- 30 (5) -NO₂;

- 45 -

R₂ is phenyl, 1-naphthyl, 2-naphthyl or thienyl which is unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of

- 5 (1) C₁-10 alkyl,
(2) R₄, and
(3) C₁-10 alkyl substituted with up to 5 groups independently selected from R₄;

R₃ is phenyl, 1-naphthyl, or 2-naphthyl which is unsubstituted or substituted with up to five substituents each of which is independently selected from the group consisting of

- 10 (1) C₁-3alkyl, wherein said alkyl is optionally substituted with from 1 to 5 halogen atoms,
(2) -O-C₁-2alkyl,
(3) -O-aryl, where the aryl group is selected from the group consisting of phenyl and naphthyl and with the proviso that said -O-aryl group is not located at the *meta* (or 3-) position when R₃ is phenyl,
(4) -O-heteroaryl,
(5) -NO₂,
20 (6) halogen,
(7) -S-CH₃,
(8) -S(O)_mC₁-2alkyl,
(9) -S(O)_mOR₈,

R₄ is

- 25 (1) -OR₈,
(2) -NO₂,
(3) halogen
(4) -S(O)_mR₁₁,
(5) -SR₈,
30 (6) -S(O)_mOR₈,
(7) -S(O)_mNR₈R₉,
(8) -NR₈R₉,
(9) -O(CR₁₀R₂₀)_pNR₈R₉,
(10) -C(O)R₈,

- 46 -

- (11) $\text{-CO}_2\text{R}_8$,
(12) $\text{-CO}_2(\text{CR}_{10}\text{R}_{20})_n\text{CONR}_8\text{R}_9$,
(13) -ZC(O)R_8 ,
5 (14) -CN ,
(15) $\text{-C(Z)NR}_8\text{R}_9$,
(16) $\text{NR}_{10}\text{C(Z)R}_8$,
(17) $\text{-C(Z)NR}_8\text{OR}_9$,
(18) $\text{NR}_{10}\text{C(Z)NR}_8\text{R}_9$,
10 (19) $\text{-NR}_{10}\text{S(O)mR}_{11}$,
(20) azido.

6. The method of Claim 1 wherein said glucagon antagonist is selected from the group consisting of:

- 15 (1) 4-(4-fluorophenyl)-2-(4-methoxycarbonylphenyl)-5-(4-pyridyl)imidazole,
(2) 2-(4-cyanophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(3) 2-(4-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
20 (4) 4-(4-fluorophenyl)-2-(4-isopropylphenyl)-5-(4-pyridyl)imidazole,
(5) 2-(4-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(6) 4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)imidazole,
25 (7) 4-(4-fluorophenyl)-2-(4-n-heptyphenyl)-5-(4-pyridyl)imidazole,
(8) 4-(4-fluorophenyl)-2-(4-phenoxyphenyl)-5-(4-pyridyl)imidazole,
(9) 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-5-(4-pyridyl)imidazole,
30 (10) 2-(4-aminophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

- (11) 2-(3-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(12) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
5 (13) 2-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(14) 4-(4-fluorophenyl)-2-(4-iodophenyl)-5-(4-pyridyl)imidazole,
(15) 2-(2,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
10 (16) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)imidazole,
(17) 2-(4-biphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(18) 4-(4-fluorophenyl)-2-(1-naphthyl)-5-(4-pyridyl)imidazole,
15 (19) 2-(4-ethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(20) 4-(4-fluorophenyl)-2-(2-naphthyl)-5-(4-pyridyl)imidazole,
(21) 2-(5-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
20 (22) 4-(4-fluorophenyl)-2-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
(23) 2-(4-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(24) 4-(4-fluorophenyl)-2-(4-methylphenyl)-5-(4-pyridyl)imidazole,
25 (25) 2-(3-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(26) 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(27) 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
30 (28) 2-(3-bromo-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

- (29) 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
5 (30) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(3-trifluoromethylphenyl)imidazole,
(31) 2-(3,4-dimethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
(32) 2-(3-chlorophenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
10 (33) 4-(3-chlorophenyl)-2-(3,4-dichlorophenyl)-5-(4-pyridyl)imidazole,
(34) 2-(4-benzyloxyphenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
(35) 2-(3,4-dichlorophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
15 (36) 2-(4-benzyloxyphenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(37) 2-(4-bromophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(38) 2-(4-(2-chloro-6-fluorobenzyl)oxy)phenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
20 (39) 2-(4-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
(40) 2-(3-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
(41) 2-(3-chlorophenyl)-4-(4-iodophenyl)-5-(4-pyridyl)imidazole,
25 (42) 2-(4-chlorophenyl)-4-(4-bromophenyl)-5-(4-pyridyl)imidazole,
(43) 2-(4-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
(44) 2-(3-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
30 (45) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(3-methyl-4-pyridyl)imidazole,
(46) 2-(4-chlorophenyl)-4-(2-fluoro-4-trifluoromethylphenyl)-5-(4-pyridyl)imidazole,

- 49 -

- 5 (47) 2-(4-chlorophenyl)-4-(2-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 (48) 4-(3-bromophenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
 (49) 4-(3-bromo-4-methoxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
 (50) 2-(4-chlorophenyl)-4-(2-ethoxyphenyl)-5-(4-pyridyl)imidazole, and
 (51) 2-(4-Azidophenyl)-4-(3-iodophenyl)-5-(4-pyridyl)imidazole.
- 10 7. A compound selected from the group consisting of:
 (1) 4-(4-fluorophenyl)-2-(4-methoxycarbonylphenyl)-5-(4-pyridyl)imidazole,
 (2) 2-(4-cyanophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
 (3) 2-(4-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
 (4) 4-(4-fluorophenyl)-2-(4-isopropylphenyl)-5-(4-pyridyl)imidazole,
 (5) 2-(4-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
 (6) 4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)imidazole,
 (7) 4-(4-fluorophenyl)-2-(4-n-heptyphenyl)-5-(4-pyridyl)imidazole,
 (8) 4-(4-fluorophenyl)-2-(4-phenoxyphenyl)-5-(4-pyridyl)imidazole,
 (9) 4-(4-fluorophenyl)-2-(4-methoxyphenyl)-5-(4-pyridyl)imidazole,
 (10) 2-(4-aminophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
 (11) 2-(3-bromophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

- 50 -

- (12) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (13) 2-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 5 (14) 4-(4-fluorophenyl)-2-(4-iodophenyl)-5-(4-pyridyl)imidazole,
- (15) 2-(2,4-dichlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (16) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(4-trifluoromethylphenyl)imidazole,
- 10 (17) 2-(4-biphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (18) 4-(4-fluorophenyl)-2-(1-naphthyl)-5-(4-pyridyl)imidazole,
- (19) 2-(4-ethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 15 (20) 4-(4-fluorophenyl)-2-(2-naphthyl)-5-(4-pyridyl)imidazole,
- (21) 2-(5-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (22) 4-(4-fluorophenyl)-2-(3-phenoxyphenyl)-5-(4-pyridyl)imidazole,
- 20 (23) 2-(4-bromo-2-thienyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (24) 4-(4-fluorophenyl)-2-(4-methylphenyl)-5-(4-pyridyl)imidazole,
- (25) 2-(3-benzyloxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 25 (26) 2-(3-chlorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (27) 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- 30 (28) 2-(3-bromo-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
- (29) 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,

- 51 -

- (30) 4-(4-fluorophenyl)-5-(4-pyridyl)-2-(3-trifluoromethylphenyl)imidazole,
(31) 2-(3,4-dimethylphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
5 (32) 2-(3-chlorophenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
(33) 4-(3-chlorophenyl)-2-(3,4-dichlorophenyl)-5-(4-pyridyl)imidazole,
(34) 2-(4-benzyloxyphenyl)-4-(3-chlorophenyl)-5-(4-pyridyl)imidazole,
10 (35) 2-(3,4-dichlorophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(36) 2-(4-benzyloxyphenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(37) 2-(4-bromophenyl)-4-phenyl-5-(4-pyridyl)imidazole,
(38) 2-(4-(2-chloro-6-fluorobenzyl)oxyphenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole,
15 (39) 2-(4-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
(40) 2-(3-chlorophenyl)-4-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
20 (41) 2-(3-chlorophenyl)-4-(4-iodophenyl)-5-(4-pyridyl)imidazole,
(42) 2-(4-chlorophenyl)-4-(4-bromophenyl)-5-(4-pyridyl)imidazole,
(43) 2-(4-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
25 (44) 2-(3-chlorophenyl)-5-(4-pyridyl)-4-(4-trifluoromethylphenyl)imidazole,
(45) 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(3-methyl-4-pyridyl)imidazole,
30 (46) 2-(4-chlorophenyl)-4-(2-fluoro-4-trifluoromethylphenyl)-5-(4-pyridyl)imidazole,
(47) 2-(4-chlorophenyl)-4-(2-phenoxyphenyl)-5-(4-pyridyl)imidazole,

- 52 -

- (48) 4-(3-bromophenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
- (49) 4-(3-bromo-4-methoxyphenyl)-2-(4-chlorophenyl)-5-(4-pyridyl)imidazole,
- 5 (50) 2-(4-chlorophenyl)-4-(2-ethoxyphenyl)-5-(4-pyridyl)imidazole, and
- (51) 2-(4-Azidophenyl)-4-(3-iodophenyl)-5-(4-pyridyl)imidazole.

10 7. A method of Claim 1 wherein said glucagon mediated disease is diabetes.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/20955

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) A61K 31/44

US CL 514/341

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/341

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3,772,441 A (LOMBARDINO) 13 November 1973.	1-7
A,P	US 5,620,999 A (WEIER et al.) 15 April 1997.	1-7
A,P	US 5,686,455 A (ADAMS et al.) 11 November 1997.	1-7

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	'T'	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"D"	Document referring to an oral disclosure, use, exhibition or other means		
"P"	Document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 12 JANUARY 1998	Date of mailing of the international search report 10 FEB 1998
------------------------------------------------------------------------------	-------------------------------------------------------------------

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer RAYMOND J. HENLEY III Telephone No. (703) 308-1235
-------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------

THIS PAGE BLANK (USPTO)